StemRIM (TSE: 4599)
Health Care · Biotechnology · JP
¥357.00
+2.59% today · +12.3% 1Y
StemRIM (TSE: 4599) operates in the Biotechnology industry within the Health Care sector. The company is valued at $140.76M and employs 45 people.
Over the last twelve months the share price has gained 12.3%, trading between 246.00 and 368.00.
Tweenvest scores StemRIM across four factors: quality 45/100. Its strongest factor is quality.
4599 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $140.76M
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -29.92
- Dividend yield
- —
- Beta (5Y)
- 0.95
- 52-week high
- ¥368.00
- 52-week low
- ¥246.00
- Avg volume (3M)
- —
- Shares outstanding
- 62.68M
- Employees
- 45
- Next earnings
- —
About StemRIM
StemRIM is a biotechnology firm dedicated to developing regenerative medicines aimed at treating severe and challenging diseases. Its product pipeline includes PJ1, a regeneration-inducing medicine based on HMGB1 peptides, which is currently undergoing Phase II clinical trials for a range of conditions such as epidermolysis bullosa, cerebral infarction, osteoarthritis, chronic liver disease, and cardiomyopathy. Beyond PJ1, StemRIM is also advancing PJ2, another regeneration-inducing medicine utilizing novel peptides A and B; PJ3, a biologic protein designed to promote regeneration; PJ4, a device for collecting a patient's own cells for therapeutic purposes; and PJ5, a stem cell-based gene therapy. Established in 2006, StemRIM is headquartered in Ibaraki, Japan.
- ISIN
- JP3399690001
- Founded
- 2006
- Listed since
- Aug 9, 2019
- Exchange
- The Tokyo Stock Exchange
- Currency
- JPY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.